 
 Title:  Levot hyroxine treatment and cardiometabolic outcomes in 
adolescents with DS  
Short Title  Aim 2  Levothyroxine  and DS  
Drug Name(s):  Levot hyroxine  
  
Regulatory Sponsor:  NIH 
eIRB  Number  12-009578  
Protocol Date:  August 26 , 2013  
Amendment 1 Date:  8/26/13 Amendment 3 Date: 11/14 /2014  
Amendment 2 Date: 9/22/14  Amendment 4 Date:  9/23/2015  
Sponsor  
NIH 
 
Study Principal Investigator  
[INVESTIGATOR_300858] , MD, MSCE  
11 NW 30 Main Building, Children’s Hospi[INVESTIGATOR_6684], 34th St. & Civic Center Blvd.  
Philadelphia, PA, [ZIP_CODE]  
Phone: [PHONE_14021]  
Email: [EMAIL_9590]  
 
 
    
   
   ii 
TABLE OF CONTENTS  
Table of Contents  ................................ ................................ ................................ ...................  ii 
Abbreviations and Definitions of Terms ................................ ................................ .............  iv 
Protocol Synopsis  ................................ ................................ ................................ ..................  vi 
Table 1: Schedule of Study Procedures: Both Groups  ................................ .......................  x 
Figure 1: Study Diagram  ................................ ................................ ................................ .... xiii 
1 BACKGROUND INFORMATI ON AND RATIONALE  ................................ ................................ ....... 1 
1.1 INTRODUCTION  ................................ ................................ ................................ ................................ ..... 1 
1.2 NAME [CONTACT_72703]  ................................ ................................ ........................  1 
1.3 FINDINGS FROM NON-CLINICAL AND CLINICAL STUDIES  ................................ ................................ ..... 1 
1.3.1  Non-Clinical Studies:  N/A  ................................ ................................ ................................ ..............  1 
1.3.2  Clinical Studies  ................................ ................................ ................................ ...............................  1 
1.4 SELECTION OF DRUGS AND DOSAGES ................................ ................................ ................................ ... 2 
1.5 RELEVANT LITERATURE AND DATA ................................ ................................ ................................ ..... 3 
1.6 COMPLIANCE STATEMENT  ................................ ................................ ................................ ....................  4 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ..............................  4 
2.1 PRIMARY AIM ................................ ................................ ................................ ................................ ...... 4 
2.2 SECONDARY AIM................................ ................................ ................................ ................................ .. 4 
3 INVESTIGATIONAL PLAN  ................................ ................................ ................................ ....................  5 
3.1 GENERAL SCHEMA OF STUDY DESIGN  ................................ ................................ ................................ . 5 
3.1.1  Screening Phase  ................................ ................................ ................................ ..............................  5 
3.1.2  Phase 1  ................................ ................................ ............................  Error! Bookmark not defined.  
3.1.3  Phase 2  ................................ ................................ ............................  Error! Bookmark not defined.  
3.1.4  Follow -up Phase  ................................ ................................ .............  Error! Bookmark not defined.  
3.2 ALLOCATION TO TREATMENT GROUPS AND BLINDING  ................................ ................................ ........  7 
3.3 STUDY DURATION , ENROLLMENT AND NUMBER OF SITES ................................ ................................ ... 8 
3.3.1  Duration of Study Participation  ................................ ................................ ................................ ...... 8 
3.3.2  Total Number of Study Sites/Total Number of Subjects Projected  ................................ ..................  8 
3.4 STUDY POPULATION  ................................ ................................ ................................ .............................  8 
3.4.1  Inclusion Criteria  ................................ ................................ ................................ ............................  8 
3.4.2  Exclusion Criteri a ................................ ................................ ................................ ...........................  8 
4 STUDY PROCEDURES  ................................ ................................ ................................ ............................  9 
4.1 SCREENING VISIT ................................ ................................ .........  ERROR ! BOOKMARK NOT DEFINED . 
4.2 SCREENING /BASELINE PHASE  ................................ ......................  ERROR ! BOOKMARK NOT DEFINED . 
4.3 INTERIM PHASE  ................................ ................................ ............  ERROR ! BOOKMARK NOT DEFINED . 
4.3.1  Visit 1 (3 Month) & Visit 2 (6 Month)  ................................ .............  Error! Bookmark not defined.  
4.4 RANDOMIZED PHASE  ................................ ................................ .... ERROR ! BOOKMARK NOT DEFINED . 
4.4.1  ................................ ................................ ................................ ..............  Error! Bookmark not defined.  
4.4.2  6 Month Visit and 12 Month Visit  ................................ ...................  Error! Bookmark not defined.  
4.5 FOLLOW -UP PHASE  ................................ ................................ ....... ERROR ! BOOKMARK NOT DEFINED . 
4.5.1  18 Month  ................................ ................................ .........................  Error! Bookmark not defined.  
4.6 TSH  & T4 CHECK  ................................ ................................ ........  ERROR ! BOOKMARK NOT DEFINED . 
4.[ADDRESS_914179] COMPLETION /WITHDRAWAL  ................................ ................................ ...............................  11 
5 STUDY EVALUATIONS AN D MEASUREMENTS  ................................ ................................ ............  12 
5.1 SCREENING AND MONITORING EVALUATIONS AND MEASUREMENTS  ................................ ................  12 
5.1.1  Laboratory Evaluations ................................ ................................ ................................ .................  14 
    
   
   iii 
5.2 SAFETY EVALUATION  ................................ ................................ ................................ .........................  15 
6 STATISTICAL CONSIDER ATIONS  ................................ ................................ ................................ .... 16 
6.1 STATISTICAL METHODS ................................ ................................ ................................ ......................  16 
6.1.1  Baseline Data  ................................ ................................ ................................ ................................  16 
6.1.2  Efficacy Analysis  ................................ ................................ ................................ ...........................  17 
6.1.3  Safety Analysis  ................................ ................................ ................................ ..............................  17 
6.2 SAMPLE SIZE AND POWER  ................................ ................................ ................................ ..................  17 
6.3 INTERIM ANALYSIS  ................................ ................................ ................................ ............................  17 
7 STUDY MEDICATION (IN TERVENTION)  ................................ ................................ ........................  19 
7.1 DESCRIPTION  ................................ ................................ ................................ ................................ ...... 19 
7.1.1  Packaging  ................................ ................................ ................................ ................................ ...... 19 
7.1.2  Labeling  ................................ ................................ ................................ ................................ ........  19 
7.1.3  Dosing  ................................ ................................ ................................ ................................ ...........  19 
7.1.4  Treatment Compliance and Adherence  ................................ ................................ .........................  19 
7.1.5  Drug Accountability  ................................ ................................ ................................ ......................  19 
8 SAFETY MANAGEMENT  ................................ ................................ ................................ .....................  20 
8.1 CLINICAL ADVERSE EVENTS  ................................ ................................ ................................ ..............  20 
8.2 ADVERSE EVENT REPORTING  ................................ ................................ ................................ .............  20 
8.3 DEFINITION OF AN ADVERSE EVENT  ................................ ................................ ................................ .. 20 
8.4 DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)  ................................ ................................ ...........  20 
8.4.1  Relationship of SAE to study drug or other intervention  ................................ ...............................  21 
8.5 IRB/IEC  NOTIFICATION OF SAE S AND OTHER UNANTICIPATED PROBLEMS  ................................ ...... 21 
8.5.1  Follow -up report  ................................ ................................ ................................ ...........................  21 
8.6 INVESTIGATOR REPORTING OF A SERIOUS ADVERSE EVENT TO SPONSOR  ................................ ..........  21 
8.7 MEDICAL EMERGENCIES  ................................ ................................ ................................ ....................  22 
9 STUDY ADMINISTRATION  ................................ ................................ ................................ .................  22 
9.1 TREATMENT ASSIGNMENT METHODS ................................ ................................ ................................ . 22 
9.1.1  Randomization ................................ ................................ ................................ ...............................  22 
9.1.2  Blinding  ................................ ................................ ................................ ................................ .........  22 
9.1.3  Unblinding  ................................ ................................ ................................ ................................ .... 22 
9.2 DATA COLLECTION AND MANAGEMENT  ................................ ................................ ............................  22 
9.3 CONFIDENTIALITY  ................................ ................................ ................................ ..............................  23 
9.4 REGULATORY AND ETHICAL CONSIDERATIONS ................................ ................................ ..................  24 
9.4.1  Data and Safety Monitoring Plan  ................................ ................................ ................................ . 24 
9.4.2  Risk Assessment  ................................ ................................ ................................ .............................  25 
9.4.3  Potential Benefits of Trial Participation  ................................ ................................ .......................  28 
9.4.4  Risk-Benefit Assessment  ................................ ................................ ................................ ................  28 
9.5 RECRUITMENT STRATEGY  ................................ ................................ ................................ ..................  28 
9.6 INFORMED CONSENT /ASSENT AND HIPAA  AUTHORIZATION  ................................ ............................  28 
9.6.1  Consent for Down syndrome subjects 18 – 20 years of age  ................................ ..........................  29 
9.6.2  Assent Procedures  ................................ ................................ ................................ .........................  30 
9.7 PAYMENT TO SUBJECTS /FAMILIES  ................................ ................................ ................................ ..... 31 
10 PUBLICATION  ................................ ................................ ................................ ................................ ........  32 
11 REFERENCES  ................................ ................................ ................................ ................................ .........  32 
 
  
    
   
   iv 
 
Abbreviations and Definitions of Terms  
   
AAP   American Academy of Pediatrics  
ABAS -II 
 
ANTITIPO  
ANTIT G  Adaptive behavior assessment system -Second edition 
parent form  
Thyroid peroxidase (microsomal) antibodies  
Thyroglobulin antibodies  
AE 
ASAQ   Adverse events  
Adolescent Sedentary Activity Questionnaire  
BES  Body esteem scale for children  
BG  Blood glucose  
BP  Blood pressure  
CEBQ  
CFQ   Child eating behavior questionnaire  
Child feeding questionnaire  
CHOP   The Children’s Hospi[INVESTIGATOR_300859]’s National Medical Center  
CPP  Central pulse pressure  
CRP   C-reactive protein  
CTRC   Clinical and Translational Research Center  
DS  Down syndrome  
DXA   Dual energy x -ray absorptiometry  
EMR  
FRS  Electronic medical record  
Stunkard figure rating scale  
HbA1c    Hemoglobin A1c  
HDL -C  High -density lipoprotein cholesterol  
HFI  Home food inventory  
HOMA -IR  Homeostasis model assessment – insulin resistance  
Hs-CRP   High -sensitivity C -reactive protein  
IL-[ADDRESS_914180] circumference  
   
   
    
   
   vi 
PROTOCOL SYNOPSIS  
Study Title  Levothyroxine treatment and cardiometabolic outcomes in 
adolescents with Down syndrome  
Funder  National Institutes of Health (NIH)  
Clinical Phase  N/A 
Study Rationale   The American Academy of Pediatrics (AAP) recommends annual 
screening for thyroid dysfunction in children and adolescents with 
Down Syndrome ( DS)(1). Mild elevations in TSH are common in 
DS.  Recently, subclinical hypothyroidism has been associated with 
increased cardiovascular ( CVD ) risk in the general adult population, 
and debate rages as to whether  subclinical hypothyroidism should 
be treated. Moreover, the potential benefits of treating subclinical 
hypothyroidism in DS are not known. This study will examine the 
effect of levothyroxine  hormone treatment on body composition, 
cardiometabolic risk ( CMR ) factors, and quality of life (QOL) in 
children with DS and subclinical hypothyroidism.  
Study Objective( s) Primary   
 To determine the effect of levothyroxine  replacement on BMI -Z, 
fat mass, and CMR factors  in pre -adolescents and adolescents 
with DS and subclinical hypothyroidism.  
 
Secondary  
  To determine the effect of levothyroxine  replacement on QOL , 
lifestyle (physical activity, nutrition) and body image  in pre -
adolescents and adolescents with DS and subclinical 
hypothyroidism.  
  
 
 
Test Article( s) 
 Levot hyroxine (starting dose 0.5 – 1 mcg/kg daily)  
 
Study Design  
 Single blinded  randomized controlled trial  using switching 
replication design . 
Subject Population  
key criteria for 
Inclusion and 
Exclusion:  Inclusion Criteria  
1. Males and females, ages 8 – 20 years  
2. Diagnosis of Down syndrome  
3. Subclinical hypothyroidism: TSH level between 5 – 10 
mIU/L, normal T4  
    
   
   vii 
 
4. Parental/guardian permission (informed consent) and if 
appropriate, child assent  
5. Females who are  [ADDRESS_914181] a negative urine/serum pregnancy test  
6. Committed to adherence to levothyroxine treatment and 
study completion  
Exclusion Criteria  
1. Pregnancy  
2. Type 1 /Type [ADDRESS_914182] 
growth, nutrition, bloo d glucose, insulin secretion, or thyroid 
function (such as lithium or certain seizure medications)  
4. Current use of levothyroxine or anti -thyroid hormone  
5.   Cyanotic congenital heart disease, or pulmonary 
hypertension (as described by [CONTACT_676215]), or congenital heart disease considered medically 
unstable by [CONTACT_676216]: 29 enrolled for 20 
completers  overall; 11 enrolled for 6 completers at CHOP  
Total number of study sites: 2: The Children’s Hospi[INVESTIGATOR_676197]’s National Medical Center  
Study Duration  Participation will last 18  months  
All subjects will be observed for 6 months  (observation period).  
Only subjects with persistently elevated TSH range ( 5-10 mlU/mL) 
at 6 months will be enrolled into 1 of 2  randomized group s.  
Group 1 : 6 months of placebo followed by 6 months of 
levothyroxine.  
OR 
Group 2 : 12 months of levothyroxine.  
 
Study Phases  
Screening  
Study Treatment  
Follow -Up    Screening  & Recruitment:  Subjects from Aim 1 (IRB#  9233 ) that 
qualify and consent to being contact[CONTACT_676217] 2.  
For subjects recruited from Aim 1, Aim 1 d ata will serve as baseline 
data and a screening visit is not necessary.  
Additional subjects will be recruited from CHOP’s Pediatric 
Research Consortium (PeRC), CNMC primary care clinics, DS 
    
   
   viii 
community events, other studies , local advertisements , local 
primary care practices , Trisomy [ADDRESS_914183] an initial interview and 
a screening  visit.  
We plan to recruit 29 subjects with the goal of 20 subjects w ho 
complete the 18 month study . 
Study Treatment : A single blinded randomized trial of 
levothyroxine treatment (starting dose 0.5 – 1 mcg/kg daily)  using a 
switching replication design. Subjects will be randomized into 2 
groups of 10. 
(Group 1)  Delayed treatment group: 6 months of placebo 
followed by 6 months of levothyroxine treatment  
(Group 2)  Immediate treatment group: 12 months of 
levothyroxine treatment  
Follow -Up: Studies will be obtained at baseline, 6 mont hs, 12 
months, and 18 months.  Int erim thyroid studies will be checked at 3 
months, 6 weeks after randomization (month 7.5); month 13.5 and 6 
weeks after any dose adjustment.  
 
Efficacy Evaluations  TSH  
T4 
Anthropometry  (HT-Z, WT -Z, BMI -Z),  
body composition  by [CONTACT_11324],  
PWV & PWA  
Blood lipid panel, non -HDL -C, lipoprotein subclass analysis, 
glucose, plasma insulin, HOMA -IR, hs-CRP, IL -6, PAI-1, 
adiponectin, leptin,  
QOL, Body Image , physical activity assessment .  
 
Safety Evaluations  To monitor for safety, data will be made available to investi gators 
every [ADDRESS_914184] mixed effects pi[INVESTIGATOR_676198] (2) will be 
used to estimate in a single model both longitudinal (within subject) 
and cross -sectional (across subject) effects of the intervention. 
Cross -sectional comparisons will be possible for the second 6 -
month period of observation when ½ of subjects will be switched to 
treatment while the other ½ will take a placebo.  
DATA AND SAFETY 
MONITORING PLAN The Biostatistics and Data Management Core (BDMC) at CHOP 
and the Investigative team will be responsible for data management. 
The Investigators will review TSH and T [ADDRESS_914185] (DSMB) will be established. The DSMB will consist of at 
least four members including a biostatistician, a developmental 
pediatrician from outside of The Children’s Hospi[INVESTIGATOR_133445], a pediatric endocrinologist, and  a senior faculty 
member with experience in clinical research and in care of children 
and adolescents with complex chronic illness. The DSMB will 
choose its chair.  Specific rules and protocols for all reviews will be 
established in a formal protocol, and approved by [CONTACT_4318], prior 
to the first DSMB meeting.  The DSMB will work jointly with the 
trial statisticians and clinical investigators to establish specific 
criteria to accomplish its tasks. The Project PI [INVESTIGATOR_676199], documenting them on an 
Adverse Experience Report (AER) form, and then reporting them 
regularly to the DSMB.     
 x   
   
   TABLE 1: SCHEDULE OF  STUDY PROCEDURES : BOTH GROUPS  
Study Phase  Observation  Treatment  
Visit  Study 
Visit #1  
(0 month)  Blood  Draw 
Visit A  
 (3 month)  Study 
Visit #2  
(6 month)  Randomiz
ation  
(no visit)  Blood draw 
Visit B  
(7.5 month)  Study 
Visit #3 
(12 month)   Blood Draw 
Visit C  
(13.5 month)   Study Visit 
#4  
(18 month)  
Study Days  1  1   1  1 
Informed 
Consent/Assent  X (written 
consent 
for 
subjects 
not 
recruited 
from IRB 
#9233)  X (verbal 
consent for 
subjects  
recruited 
from IRB 
#9233)  X (written 
consent 
for 
subjects 
recruited 
from IRB 
#9233)       
Review 
Inclusion/Exclusion 
Criteria  X        
Demographics/  Medical 
History  X  X   X  X 
Vital Signs: BP, HR, 
RR X  X   X  X 
Height and Weight  X  X   X  X 
Pregnancy Test  X  X   X  X 
Prior/Concomitant 
Medications  X  X   X  X 
DXA Full Body   X  X   X  X 
Fasting blood glucose  X  X   X  X 
Fasting plasma insulin  X  X   X  X 
HOMA -IR X  X   X  X 
PWV & PWA  X        
Echocardiography  X        
 xi   
   
   Study Phase  Observation  Treatment  
Visit  Study 
Visit #1  
(0 month)  Blood Draw 
Visit A  
 (3 month)  Study 
Visit #2  
(6 month)  Randomiz
ation  
(no visit) Blood draw 
Visit B  
(7.5 month)  Study 
Visit #3 
(12 month)   Blood Draw 
Visit C  
(13.5 month)   Study Visit 
#4  
(18 month)  
Anthropometry  X  X   X  X 
QOL and Body Image 
questionnaires  X  X   X  X 
Pubertal Status  X  X   X  X 
Smoking status  
 X        
Fasting lipid panel: TG, 
TC, HDL -C, LDL -C X  X   X  X 
Non-HDL -C X  X   X  X 
HbA1C  X  X   X  X 
PAI-1 X  X   X  X 
Hs-CRP  X  X   X  X 
IL-6 X  X   X  X 
Adiponectin  X  X   X  X 
Leptin  
 X  X   X  X 
Lipoprotein subclass 
analysis  X  X   X  X 
T4 X X X  X X X X 
TSH  X X X  X X X X 
ANTITPO   X       
ANTITG   X       
Physical activity 
armband (Worn for 7 
days after study visit)  X  X   X  X 
Randomization     X      
 xii   
   
   Dispense study 
medication (placebo or 
levothyroxine)     X      
Dispense levothyroxine 
– both groups       X   
Dietary intake  XXX   XXX    XXX   XXX  
Drug Compliance      X X X X 
Adverse Event s      X X X X 
 
 
 
 
 
 
  
 
 
 page xiii Protocol No. XXXXX   
   
   FIGURE 1: STUDY DIAG RAM  
     
 
                                                                     
 
 
                                                                      
 
 
 
 
 
 
 0 month:  Study Visit #1  
3 month:  
Blood Draw Visit A  
6 month: Study Visit #2  
   
Delayed Treatment 
Group  Immediate 
Treatment Group  
Dispense p lacebo  
(6-12 month)  
12 month : 
Study Visit #3  
Dispense levothyroxine (12 -18 month)  
18 month : 
Study Visit #4  
 Dispense 
levohyroxine  
(6-12 month)  
12 month : 
Study Visit #3  
Continue levothyroxine  (12-18 month)  
 
18 month : 
Study Visit #4  Subjects with persistently 
elevated TSH  
(5-10 mlU/mL ) 0-6 month : Observation Phase  
7.5 month:  
Blood Draw Visit B  7.5 month:  
Blood Draw Visit B  
13.5 month:  
Blood Draw Visit B  13.5 month:  
Blood Draw Visit B  Randomiz ation  
  Protocol No. XXXXX  
   
   1 
1 BACKGROUND INFORMATI ON AND RATIONALE  
 
1.1 Introduction  
The AAP recommends yearly screening of thyroid studies in Down syndrome ( DS)(1). 
Clinical experience suggests  that TSH  concentrat ions in the subclinical hypothyroid range 
(5-10 mIU/L)  are not uncommon in DS, but the benefits and risks of treating subclinical 
hypoth yroid ism (SCH)  in the DS population are not known.  In adults, SCH has been 
associated with increased cardiometabolic risk and individuals with DS may be at increased 
cardiometabolic risk as well . Thus, this preliminary study will explore the effects of 
levothyroxine treatment of subclinical hypothyroidsim on cardiometabolic risk and 
quality of life in pre -adolescents and adolescents with DS.  This is part of the larger 
study, IRB #9233, investigating cardiometabolic risk in the DS population .  
1.2 Name [CONTACT_676245] : Group 1 (delayed treatment) and Group 2 (immediate treatment)  will 
receive a starting dose of 0.5 -1 mcg/kg/day. Group 1 will receive levothyroxine treatment at 
the 12th month and continue treatment until the 18th month. Group 1 will receive a total of 6 
months of levothyroxine treatment. Group 2 will receive levothyroxine treatment at the  6th 
month and continue treatment until the 18th month. Group 2 will receive a total of 12 months 
of levothyroxine treatment.  
Placebo : Group 1 (delayed treatment) will receive placebo for the first 6 months.  
Investigators will be unblinded to permit titration of levothyroxine dose s. Dose adjustments 
will be made at the discretion of the PI. TSH will be repeated 6 weeks after any dose 
adjustment.  
1.3 Findings from Non -Clinical and Clinical Studies  
1.3.1 Non-Clinical Studies :  N/A  
1.3.2 Clinical Studies  
[IP_ADDRESS]  Human Pharmacokinetics : N/A  
 
[IP_ADDRESS]  Clinical Studies in Adults  
Subclinical hypothyroidism in adults is associated with increased risk of incident ischemi c 
heart disease and related mortality, an effect that may be attenuated by [CONTACT_676218](3). The mechanisms linking subclinical hypothyroidism and CVD remain to be 
delineated but have been reviewed  by [CONTACT_676219](4). Studies of CVD risk in patients 
with subclinical hypothyroidism have shown: 1. arterial stiffness identified by [CONTACT_676220](5); 2. endothelial dysfunction was present  (6, 7), which  
improved with levothyroxine  treatment(8); 3. and elevated CRP was present in some(9-11) but 
not all(12) studies. Data on lipogenic profiles were also conflicting: LDL and total  
  Protocol No. XXXXX  
   
   2 
cholesterol(10, 13, 14) were higher in some studies (an effect potentially mediated through 
insulin resistance(15)) but not in other studies(12, 14). In an RCT, levothyroxine  treatment 
didn’t im prove total cholesterol and LDL , but a sub -analysis suggested benefit for subjects 
with TSH>12 mIU/L or with elevated LDL(16). Debate remains whether adults with 
subclinical hypothyroidism should be treated(17). 
 
[IP_ADDRESS]  Clinical Studies in Children  
Data in children with subclinical hypothyroidism are limited. Despi[INVESTIGATOR_676200], evidence to guide management of marginally elevated 
TSH (with normal T4) in children with DS is equally sparse. In non -DS children,  TSH>4.65 
mIU/L was associated with lower HDL(18). One year of levothyroxine  treatment in children 
with subclinical hypothyroidism and short statur e improved growth velocity(19). Left 
ventricular function and LV mass (by [CONTACT_51541]) was not different in 16 children 
with DS and subclinical hypothyroidism (TSH>6.5 mIU/L; mean TSH = 7.8 mIU/L) vs. 25 
children with DS and norma l TSH. However, these findings may be limited by [CONTACT_676221]. An intervention study of 7 subjects age 2 -42 years with DS and 
“hypothyroidism ” defined as low T4 and normal or elevated TSH (0.2 -18.9 mIU/L) on 8 
weeks of levothyroxine  treatment did not improve developmental or functional outcomes. 
Anthropometrics and CMR factors were not examined (20). In contrast, increased TSH in the 
absence of overt congenital hypothyroidism is common in neonates with DS(21) and 
prompted an RCT in  181 neonates with DS. TSH -directed levothyroxine  treatment was 
associated with better growth, weight gain, and motor development after 24 months 
compared to placebo(22). These findings highlight that the “asymptomatic ” component of 
subclinical hypothyroidism may have medically -relevant effects.  
 
1.4 Selection of Drugs and Dosages  
Levothyroxine (T4) is a synthet ic form of thyroxine, an endogenous hormone secreted by 
[CONTACT_516778]. T4 is converted to its active metabolite, L -triiodothyronine (T3). Thyroid 
hormones (T4 and T3) then bind  to thyroid receptor proteins in the cell nucleus and exert 
metabolic effect s through control of DNA transcription and protein synthesis . Thyroid 
hormones are  involved in normal metabolism, growth, and development , promote 
gluconeogenesis, increase  utilization and mobilization of glycogen stores,  stimulate  protein 
synthesis,  and increase  basal metabolic rate .  Onset of action for the oral form  of 
levothyroxine  is 3-5 days.  Oral tablets are available in a number of doses:  25 mcg, 50 mcg, 
75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 300 
mcg.  In ch ildren, pi[INVESTIGATOR_676201]:  37.5 mcg, 44 mcg, 
56 mcg, 62.5 mcg, 68.5 mcg.  Younger children tend to require higher doses for body weight 
of thyroxine replacement  than older children and adults with hypothyroidism (TSH >10 
mIU/L) . 
Typi[INVESTIGATOR_676202],  based on age , are: a ge 6-12 year : 4-5 
mcg/kg/day; age > 12 years : 2-3 mcg/kg/day; adults and in older children in whom growth is 
complet e: 1.7 mcg/kg/day.  For subclinical hypothyroidism , a starting dose of 0.5 -1 
  Protocol No. XXXXX  
   
   3 
mcg/kg/day is typi[INVESTIGATOR_2855].  For the purposes of this study, subjects will be initiated on a dose 
between 0.5-1 mcg/kg/day , depending on the available tablet formulations and the PI’s  
medical discretion. TFTs will be checked 6 weeks after treatment  initiation and titrated to 
achieve TSH 0.5-3 mIU/L range.  
Generic lactase tablets will be used as placebo and will be dispensed by [CONTACT_676222].  
 
1.5 Relevant Literature and Data  
The AAP recommends yearly screening of thyroid studies in DS(1)and reports a 4 -18% risk 
of hypothyroidism, with risk increasing with age. The TSH threshold for defining 
hypothyroidism varies among studies(23). Symptoms suggestive of hypothyroidism --
constipation, dry skin, weight gain, and decreased growth velocity —are not uncommon in 
children with DS(23). Studies in DS suggest TSH is often higher than the normal population 
and occurs in the presence of normal thyroxine concentration, a phenomenon referred to as 
subclinica l hypothyroidism or isolated hyperthyrotopi[INVESTIGATOR_676203]. The clinical relevance of 
isolated increased TSH is unknown and there is little data to guide clinical management. 
Rates of medically treated thyroid disease (>95% with thyroid hormone replacement) in 
child ren with DS enrolled in Tennessee Medicaid increased by 73% from 1995 to 2003 
(22.37/1000 child years) subsequent to the 2001 AAP guideline publication. They estimated 
a 10.8% population based incidence of thyroid dysfunction in 1257 children with DS(24). The 
prevalence of overt hypothyroidism was not reported, and the question remains whether 
children with DS and subclinical hypothyroidism are being treated.  
Subclinical hypothyroidism in adults is associated with increased risk of incident ischemic 
heart disease and related mortality, an effect that may be attenuated by [CONTACT_676218](3). As described in section ([IP_ADDRESS]), CVD risk may be higher in adults with SCH(4-
15), and levothyroxine  treatment may reduce CVD risk in adults with SCH(16). 
 
Subclinical Hypothyroidism in Children and DS  
Data in children with subclinical hypothyroidism are limited. Despi[INVESTIGATOR_676200], evidence to guide management of elevated TSH in 
children with DS is equally sparse. In non -DS children, TSH>4.65 mIU/L was associated 
with lower HDL(18). One year of levothyroxine  treatment in short children with subclinical 
hypothyroidism and short stature improved growth velocity(19). Lef t ventricular function and 
LV mass (by [CONTACT_51541]) was not different in 16 children with DS and subclinical 
hypothyroidism (TSH>6.5 mIU/L; mean TSH = 7.8 mIU/L) vs. 25 children with DS and 
normal TSH. However, these findings may be limited by [CONTACT_676223]. An 
intervention study of 7 subjects age 2 -42 years with DS and hypothyroidism , defined as low 
T4 and normal or elevated TSH (0.2 -18.9 mIU/L) on 8 weeks of levothyroxine  treatment did 
not improve developmental or functional outcomes. Anthrop ometrics and CMR factors were 
not examined(20). In contrast, in creased TSH in the absence of overt congenital 
hypothyroidism is common in neonates with DS(21) and prompted an RCT in 181 neonates 
with DS. TSH -directed levothyroxine  treatmen t was associated with better growth, weight 
gain, and motor development after 24 months compared to placebo(22). These findings 
  Protocol No. XXXXX  
   
   4 
highlight that the “asymptomatic ” component of subclinical hypothyroidism may have 
medically -relevant effects. This aim will provide potentially clinically relevant 
prelimina ry evidence for the treatment  of subclinical hypothyroidism in DS.  
1.6 Compliance Statement  
This study will be conducted in full accordance with all applicable Children’s Hospi[INVESTIGATOR_171708]’s National Medical Center Research Policies and Pro cedures and 
with all applicable Federal and state laws and regulations including 45 CFR 46, 21 CFR 
Parts 50, 54, 56, 312, 314 and 812 and the Good Clinical Practice: Consolidated Guideline 
approved by [CONTACT_5787] (ICH ). All epi[INVESTIGATOR_1865] s of 
noncompliance will be documented.  
The investigators will perform the study in accordance with this protocol, will obtain 
consent and assent, and will report unanticipated problems involving risks to subjects or 
others  in accordance with The C hildren’s Hospi[INVESTIGATOR_300863]’s National 
Medical Center IRB Policies and Procedures and all federal requirements. Collection, 
recording, and reporting of data will be accurate and will ensure the privacy, health, and 
welfare of research s ubjects during and after the study.  
[ADDRESS_914186] of levothyroxine replacement on non-HDL -C levels in pre -
adolescents and adolescents with DS and subclinical hypothyroidism . Primary h ypothesis : 
We hypothesize levothyroxine treatment of subclinical hypothyroidism will  decrease non -
HDL -cholesterol in DS  
 
 
2.2 Secondary Aim  
1) To explore the effect of levothyroxine replacement on small LDL -P, fat mass, BMI Z 
score, and inflammation in pre -adolescents and adolescents with subclinical 
hypothyroidism and DS. Hypothesis: We hypothesize thyroxine treatment of 
subclinical hypothyroidi sm will  decrease  small LDL -P, decrease fat mass, decrease 
BMI Z score, and decrease inflammation  
2) To determine the effect of levothyroxine replacement on QOL, lifestyle (physical 
activity, nutrition) and body image in pre -adolescents and adolescents with DS  and 
subclinical hypothyroidism.   Hypothesis : Treatment  of subclinical hypothyroidism 
will be associated with improved QOL , physical activity, and body image in pre -
adolescents and adolescents with DS and subclinical hypothyroidism.  
 
  Protocol No. XXXXX  
   
   [ADDRESS_914187] at the CHOP outpatient 
CTRC  and at Children’s National Medical Center . Subjects with Down syndrome and 
subclinical hypothyroidism (TSH: 5 -10 mIU/L) ages [ADDRESS_914188] has a TSH which has reverted to normal at 3  months, they 
will continue on to the 6 -month check.  Only subjects with persistently elevated TSH (5 -10 
mIU/mL) at [ADDRESS_914189] 
definition of “persistently elevate d,” in this study, we consider TSH level that is 5-10 mIU/L 
at 0 and 6 months as “persistently elevated.”  If TSH is < 5 mIU/L at [ADDRESS_914190] has a history of TSH 5 -10 mIU/L, a repeat TSH may be drawn, at the discretion of 
the principle investi gator, within 3 -6 months; if TSH is < 5 mIU/mL at 6 months, a repeat 
TSH may be drawn, at the discretion of the investigator, within 1 -2 weeks. If the repeat TSH 
is < 5 mIU/L, the subject will not be eligible to continue. If TSH is > 10 m IU/L during the 
first 6 months, a repeat TSH will be drawn within 1 -2 week s. If the repeat TSH is > 10 
mIU/L, thyroid dysfunction will not be considered subclinical. The subject will be referred 
to an endocrinologist for definitive therapy. After 6 months of observation, su bjects will be 
randomized to: Group 1 (6 months of placebo, followed by 6 months of levothyroxine) or 
Group 2 ( 12 months of levothyroxine). The initial levothyroxine dose will be 0.5 – 1 
mcg/kg/day, with a goal of TSH desired range of 0.5 – 3 mIU/L. Subjec ts/families will be 
blinded to the treatment arm. Investigators will be unbl inded to permit titration of 
levothyroxine dose. TSH and T4 will be measured after 6 weeks (month 7.5) of 
levothyroxine/placebo commencement (as a measure of efficacy of levothyroxine dose), and 
then at month 12. At month 12, levothyroxine will be initiated in Group 1 (delayed 
treatment), allowing for 6 months of treatment. Group 2 (immediate treatment) will continue 
an additional 6 months of levothyroxine (12 months total). T SH will be checked at 6 weeks 
(month 13.5) and at month 18 in both groups. Dose adjustments will be mad e at the 
discretion of the PI . TSH will be repeated 6 weeks after any dose adjustments , which may be 
in addition to the time points above if necessary . This switching replication design will 
permit using each child to serve as his/her own control and provides a placebo control period 
for each treated child .  The goal is for 20 subjects to complete the 18 month study.  
3.1.1 Screening Phase  
Potential subjects will  be identified using the protocol inclusion and exclusion criteria. With 
their permission, subjects may be screened and recruited from Aim 1: Cardio risk factors in 
DS youth (IRB #12 -009233), which is recruiting male and female subjects with Down 
syndrome in the age range of [ADDRESS_914191] review to determine eligibility will be conducted on subjects 
who are not recruited from #9233.  
  Protocol No. XXXXX  
   
   [ADDRESS_914192] TSH >10 mIU/L during the [ADDRESS_914193] within 1 -2 week s. If the repeat TSH is >10 mIU/mL, the subject not 
be considered to hav e subclinical hypothyroidism and will not qualify to continue the study . 
They will be referred to an endocrinologist for treatment.  Subjects who have TSH <5 mIU/L 
at the [ADDRESS_914194] within 1 -2 weeks; this will be at the 
discret ion of the study investigator. If TSH or repeat TSH (if applicable) is <5 mIU/L, the 
subject will be considered to have normal levels of TSH and will not qualify to continue the 
study. Subjects who have a history of subclinical hypothyroidism, but at the [ADDRESS_914195] within 3 -6 months; this 
will also be at the discretion of the study investigator.  
 
Study Visit #1 (0 Month): - For subjects recruited from #9233, #9233 data will serve as 
Study Visit #1 data. Study visit #1 will not be necessary for subjects recruited from #9233.  
Subjects who have not participated in Study #9233 will complete Study Visit #1. Subject s 
and their par ents/guardians will come  to the research facility  following a [ADDRESS_914196]. Parental/guardian /Legal Authorized Representative  consent and child assent (if child is 
deemed capable of assent) will be obtained prior to any study procedures being per formed. 
Females will receive a urine pregnancy test. Females found to be pregnant will be 
disqualified from the study and will receive appropriate counseling and referral. Study 
participants will have the following measures: fasting blood samples, TSH, T4 , 
anthropometric measurements, whole body DXA scan, blood pressure, pubertal assessment, 
pulse wave velocity & pulse wave analysis, echocardiography and questionnaire 
assessment s. After the study visit, subjects will be asked to wear a  physical activity arm  
band at home for 7 days , and a 3 day dietary recall will be done by [CONTACT_756] . 
Blood Draw Visit A( 3 Month ):– During this observation time frame, subject s will have a 
blood draw to check TSH and T4 levels. This blood draw can be done at the research facili ty 
or at other hospi[INVESTIGATOR_307] -affiliated  sites. 
Study Visit #2 ( 6 Month ): – Subjects and their parents/guardians will present to the 
research facility  following an overnight fast. At this study visit, the subject will have the 
following measures: fasting blood samples, TSH, T4, anthropometric measurements, whole 
body DXA scan, blood pressure, pubertal assessment and questionnaire assessments. 
Females wi ll receive a urine pregnancy test.  Females found to be pregnant will be 
disqualified from the study and will receive appropriate counseling and referral.  After the 
study visit, subjects will be asked to wear a physical activity arm band at home for 7 days , 
and a 3 day dietary recall will be done by [CONTACT_756].  
3.1.3 Treatment Phase  
Randomization and blinding  -  
  Protocol No. XXXXX  
   
   7 
Only subjects with persistently elevated TSH (5 – 10 m IU/mL) will be randomized into the 
following 2 groups of 10: Group 1 (Delayed treatment) or Group 2  (Immediate treatment).A 
[ADDRESS_914197] been randomized into 
Group 1 and a 3-month supply of levothyroxine will be dispensed to subjects randomized 
into Group 2.  
Blood Draw Visit B  (7.5 Month) : TSH and T 4 will be measured 6 weeks after the Study 
Visit #2 (approximately 7.5 months from the start of the study) . Subjects will obtain  a blood 
draw. Dose adjustments will be made for Group 2  as needed .  Another 3 -month supply of 
placebo or levothyroxine (dose ad justed as necessary) will be mailed to the home.  Subjects 
requiring dose adjustments will have TSH and T4 in another 6 weeks to confirm/assure TSH 
is in the desired range.  
Study Visit #3 ( 12 Month ): – Subjects and their parents/guardians will present  to the 
research facility  following a  12-hour overnight fast. At this study visit, the subject will have 
the following measures: fasting blood samples, TSH, T4, anthropometric measure ments , 
whole body DXA scan, blood pressure, pubertal assessment  and questi onnaire assessments . 
Females will  receive a urine pregnancy test.  Females found to be pregnant will be 
disqualified from the study and will receive appropriate counseling and referral.  After the 
study visit, subjects will be asked to wear a physical activ ity arm band at home for 7 days, 
and a 3 day dietary recall will be done by [CONTACT_756] . TSH and T4 will be reviewed and 
levothyroxine will now be dispensed to both Groups 1 and 2.   Group 2 will continue on 
current dose if TSH within range; otherwise dose ad justments will be made as necessary.  
Blood Draw Visit C ( 13.5 Month ): TSH and T4 will be measured 6 weeks after the 12 
month visit  (approximately 13.5 months from the start of the study) . Subjects will have 
blood drawn.  A subsequent blood draw 6 weeks later will be required for any dose 
adjustments.  
Study Visit #4 ( 18 Month ): – Subjects and their parents/guardians will present for a final 
follow up at  research facility  following a  12-hour overnight fast. At this study visit, the 
subject will have the following measures: fasting blood samples, TSH, T4, anthropometric 
measurements,whole body DXA scan, blood pressure, pubertal assessment and 
questionnaire assessments. Females will receive a urine pregnancy test. Females found to be 
pregnant will be di squalified from the study and will receive appropriate counseling and 
referral.  After the study visit, subjects will be asked to wear a physical activity arm band at 
home for 7 days, and a 3 day dietary recall will be done by [CONTACT_756] . 
 
3.2 Allocation to Tre atment Groups and Blinding  
Randomization and allocation concealment: Children will be randomized to two groups. 
Both will be observed for [ADDRESS_914198] 
statisticians and implemented using opaque sealed envelopes to ensure allocation 
concealment. Balance between treatment arms will be mainta ined by [CONTACT_676224] (two 
  Protocol No. XXXXX  
   
   8 
strata , male and female and age (two strata, ages 8 -14 and ages 14 -20). After envelopes are 
opened, treatment assignment will be blinded to th e subjects (and their parents).  
3.[ADDRESS_914199] will be between 6 to 18 months .  
3.3.2 Total Number of Study Sites/Total Number of Subjects Projected  
The study wi ll be conducted at 2 study site s, The Children’s Hospi[INVESTIGATOR_676204]’s National Medical Center .  Interim blood draws may take place at satellite 
Children’s Hospi[INVESTIGATOR_300863]’s National Medical Center sites, if it is 
more convenient for the family.  
It is expected that approximately 29 subjects will be enrolled to yield  20 study completers .   
3.4 Study Population  
3.4.1 Inclusion Criteria  
Inclusion Criteria  
1. Males and females, ages 8 – 20 years  
2. Diagnosis of Down syndrome  
3. Subclinica l hypothyroidism: TSH level between 5 – 10 mIU/L, normal T4  
4. Parental/guardian permission (informed consent) and if appropriate, child assent  
5. Females who are  [ADDRESS_914200] a negative 
urine/serum pregnancy test  
6. Committed to adherence to levothyroxine  treatment and study completion  
3.4.2 Exclusion Criteria  
Exclusion Criteria  
1. Pregnancy  
2. Type 1/Type [ADDRESS_914201] growth, nutrition, blood 
glucose, insulin secretion, or thyroid function (such as lithium or certain seizure 
medications)  
4. Current use of levothyroxine  or anti -thyroid hormone  
5.   Cyanotic congenital heart disease, or pulmonary hypertension (as described by [CONTACT_676225]), or congenital  heart disease considered medically 
unstable by [CONTACT_676226]. Any violations 
of these criteria must be reported in accordance with IRB Policies and Procedures.  
  Protocol No. XXXXX  
   
   [ADDRESS_914202] review will be done to assess eligibility for the 
study.  
4.2 Observation Phase  
4.2.1 Study Visit #1 (0 Month), Blood Draw Visit A (3 Month) & Stud y Visit #2 (6 
Month)  
The purpose of the 3 Observation Phase visits is to observe TSH and T4 levels over a period 
of 6 months. All subjects will get a blood draw for TSH and T4 labs 3 months after the 
Study Visit #1. The TSH and T4 at 0 and 6 months will be  done as part of Study Visit #1 
and #2 .At the PI’s discretion, additional blood draws following the [ADDRESS_914203] to assess TSH levels.  
The following visits and procedures occur during the Observation Phase:  
Study Visit #1  (0 month) = 1 visit lasting approximately 4.5 hours  
 Informed Consent: 30 minutes /as long as needed for parent/guardian/participant to 
fully comprehend the study involvement  
 Fasting blood draw: 15 minutes  
 Pubertal Status Exam: 5 minutes  
 Vital Signs: 10 minutes  
 DXA scan: 10 minutes  
 Anthropometric measurements: 15 minutes  
 PWV and PWA: 30  minutes  
 Echocardiography: 20 minutes  
 Family history: 10 minutes  
 Questionnaire assessments ( PedsQL, IWQOL, BES, FRS, ASAQ, CEBQ, CFQ, 
ABAS -II, HFI ): 1.[ADDRESS_914204] and parent/guardian . HFI 
will be mailed to family and completed prior to visit.  
 Physical activity armband (worn at home for 7 days)  
 3 day dietary recalls over the phone from home = Approximately 30 minutes for 
each diet recall.  
Blood Draw Visit  A (3 month) = Approximately 15 minutes for blood draw  
 TSH &T4 b lood draw: 15 minutes  
 
Study Visit #2 (6 month)  = 1 visit lasting approximately 4 hours  
 Fasting blood draw: 15 minutes  
  Protocol No. XXXXX  
   
   10 
 Pubertal Status Exam: 5 minutes  
 Vital Signs: 10 minutes  
 DXA scan: 10 minu tes 
 Anthropometric measurements: 15 minutes  
 Family history: 10 minutes  
 Questionnaire assessments ( PedsQL, IWQOL, BES, FRS, ASAQ, CEBQ, CFQ, 
ABAS -II, HFI : 1.[ADDRESS_914205] and parent/guardian . HFI 
will be mailed to family and completed prior to visit.  
 Physical activity armband (worn at home for 7 days)  
 3 day dietary recalls over the phone from home = Approximately 30 minutes for 
each diet recall.  
4.3 Treatment  Phase  
4.3.1 Randomization  
After Study Visit #2 (6 months), only subjects with persistently elevated TSH (5 -10 
mlU/mL) will be randomized into two groups of 10. Randomization will be performed 
centrally by [CONTACT_676227]. Balance between treatment arms will be maintained by [CONTACT_676228] (two strata, male and female) and age (two strata, ages 8 -14 and ages 14 -20). After 
envelopes are opened, treatment assignment will be blinded to the subjects and their 
parents/guardians.  
The following visits and procedures will occur during the Treatment Phase:  
Blood Draw Visit B  (7.5 month) : Approximately 15 minutes for blood  draw  
TSH and T4 blood draw will be done 6 weeks after the 6 month visit (at 7.5 months) as a 
measure of efficacy of levothyroxine dose.  
Study Visit #3 (12 month)  = 1 visit lasting approximately 4 hours  
 Fasting blood draw: 15 minutes  
 Pubertal Status Exam: 5 minutes  
 Vital Signs: 10 minutes  
 DXA scan: 10 minutes  
 Anthropometric measurements: 15 minutes  
 Family history: 10 minutes  
 Questionnaire assessments ( PedsQL, IWQOL, BES, FRS, ASAQ, CEBQ, CFQ, 
ABAS -II, HFI ): 1.[ADDRESS_914206] and par ent/guardian . HFI 
will be mailed to family and completed prior to visit.  
 Physical activity armband (worn at home for 7 days)  
 3 day dietary recalls over the phone from home = Approximately 30 minutes for 
each diet recall.  
Blood Draw Visit C  (13.5 month) :  Approximately 15  minutes  for blood draw  
  Protocol No. XXXXX  
   
   11 
TSH and T4 blood draw will be done 6 weeks after the 12 month visit  (at 13.5 months)  as a 
measure of efficacy of levothyroxine dose . 
Study Visit #4 (18 month)  = 1 visit lasting approximately 4 hours  
 Fasting blood dr aw: 15 minutes  
 Pubertal Status Exam: 5 minutes  
 Vital Signs: 10 minutes  
 DXA scan: 10 minutes  
 Anthropometric measurements: 15 minutes  
 Family history: 10 minutes  
 Questionnaire assessments ( (PedsQL, IWQOL, BES, FRS, ASAQ, CEBQ, CFQ, 
ABAS -II, HFI ): 1.[ADDRESS_914207] and parent/guardian . HFI 
will be mailed to family and completed prior to visit.  
 Physical activity armband (worn at home for 7 days)  
 3 day dietary recalls over the phone from home = Approximately 30 minutes for 
each diet recall.  
4.4 Blood Draw Visits B & C  
Randomized subjects will be asked to have a blood draw to check TSH and T4 levels [ADDRESS_914208] the levothyroxine dose if the PI  [INVESTIGATOR_63718] s 
necessary.  
4.5 Concomitant Medication  
After the participant has completed the screening and interim visits, the participant will be 
randomized to take an oral placebo or levothyroxine treatment. The initial levothyroxine 
dose will be 0.5 -1 mcg/kg/day.  Participants are required to bring in their full or partially full 
bottles of placebo/ levothyroxine to each study visit ( Study Visits #3 and 4 ).  Subjects can 
continue other medications ; these will be recorded at ea ch study visit.  
4.[ADDRESS_914209] Completion/Withdrawal  
Subjects may withdraw from the study at any time without prejudice to their care.  They 
may also be discontinued from the study at the discretion of the Investigator for lack of 
adherence to study treatment, visit schedul es, or AEs .  The Investigator or the Sponsor (if 
applicable) may also withdraw subjects who violate the study plan, or to protect the subject 
for reasons of safety or for administrative reasons.  It will be documented whether or not 
each subject  completes the clinical study. If the Investigator becomes aware of any serious, 
related adverse events after the subject completes or withdraws from the study, they will be 
recorded in the source documents and on the CRF.  
  Protocol No. XXXXX  
   
   12 
5 STUDY EVALUATIONS AN D MEASUREMEN TS 
 
5.1 Screening and Monitoring Evaluations and Measurements  
 Fasting blood draw: This will be completed by [CONTACT_75462]. A total of 
approximately 12.5 mL (approximately 2½ teaspoons) of blood will be obtained.  
 
 Pubertal Status Exam: Tanner staging of puberty  will be performed by a pediatric 
endocrinologist team member. This exam will take place in a private exam room.  
 
 Vital Signs: Blood pressure, heart rate, and respi[INVESTIGATOR_676205]. The blood pressure will be taken 3 times and  averaged. Vital signs will 
be collected after the blood draw.  
 
 Full Body DXA S can: The DXA scan will be performed by [CONTACT_23872] . The scan 
measures BMC, BMD, BMD -Z, fat mass, lean body mass, total mass, fat -free mass 
and percent fat.   
 
 Anthropometr y: Weight  will be measured by [CONTACT_300897] (Scaletronix) 
and stature on a stadiometer (Holtain). Body proportions and fat distribution 
measurements (sitting height, arm and waist circumference, and skin fold thickness 
at triceps, biceps, subscapular, an d suprailiac sites) will be measured.  
 
 Pulse Wave Velocity (PWV) and Pulse Wave Analysis (PWA): Aortic PWV and 
PWA will be measured  by a trained technician.  PWV and PWA will only be done at 
Study Visit #1 . 
 
 Echocardiography: LV mass will be measured by [CONTACT_676229] a trained 
technician. Echocardiography will only be done at Study Visit #1 . 
 
 Family History: The study coordinator/appropriate member of the investigative team 
will administer the CRF to collect relevant patient medical history, family history of 
CVD/dyslipi[INVESTIGATOR_035]/T2DM.  
 
 Questionnaire Assessments: The following questionnaires: (PedsQL , IWQOL, BES,  
FRS, ASAQ , CEBQ, CFQ, ABAS -II, body satisfaction scales ) will be administered 
by [CONTACT_9137]/appropriate member of the investigative team. Each 
questionnaire will be verbally communicated to the parent/participant, and the team 
member will show t he questions as they are read, as appropriate.  The HFI  and 
physical activity/armband diary  will be self -administered at home.  
 
 PedsQL  - The Pediatric Quality of Life Inventory uses a modular 
approach to measuring health related QOL in healthy children, 
adolescents, and those with acute and chronic health conditions. Scales 
include: 1) physical functioning, 2) emotional functioning, 3) social 
  Protocol No. XXXXX  
   
   13 
functioning, and 4) school functioning, which yield summary scores of a 
total scale score, a psychosocial health summ ary score, and the physical 
health summary score.  
 
 IWQOL -Kids  - The Impact of Weight on Quality of Life – Kids 
(IWQOL -Kids) © is a validated self -report measure of weight -related 
quality of life for youth ages 11 -19. This condition -specific QOL 
assessment is a 27 item questionnaire that yields a total score and 4 
domain scores, including physical comfort, body esteem, social life, and 
family relations. It has been used in children, adolesce nts, and in special 
populations.  
 
 IWQOL -Kids – Parent Form - The Imp act of Weight on Quality of  Life 
Kids  – Parent Form  (IWQOL -Parents ) is a measure of the parent 
perception of weight -related quality of life. This condition -specific QOL 
assessment is a 27 item questionnaire that yields a total score and 4 
domain scores, in cluding physical comfort, body esteem, social life, and 
family relations.  
 
 BES – the Body Esteem Scale for Children  is a 20 -item, yes/no 
questionnaire designed to assess children’s attitudes and feelings about 
their body and appearance.  
 
 FRS  – The Stunka rd Figure Rating Scale depi[INVESTIGATOR_27039] 9 male and 9 female 
figures, ranging in size from very thin to very overweight. It is used to 
assess perceptions of current and ideal body size.  
  
 ASAQ -   The Adolescent Sedentary Activity Questionnaire is a reliable 
assessment of a comprehensive range of sedentary behaviors that occur in 
school -aged young people. In this measure, the parent will estimate the 
amount of time spent engaging in various sedenta ry activities during each 
day of a typi[INVESTIGATOR_300866].  
 
 CEBQ – The Child Eating Behavior Questionnaire is a reliable and valid, 
35 item questionnaire measuring appetite and eating style (satiety 
responsiveness, food enjoyment, food responsiven ess, slowness in eating, 
food fussiness, desire to drink, emotional over -eating and emotional 
under -eating).  
 
 CFQ – The Child Feeding Questionnaire measures parental feeding 
practices, assessing parental beliefs, attitudes, and practices regarding 
child feeding. It is designed for parents of children in the age range of 2 -
11 years of age.  
 
  Protocol No. XXXXX  
   
   14 
 
 ABAS -II – The Adaptive Behavior Assessment System -Second Edition is 
widely used to evaluate individuals with intellectual and developmental 
disabilities measuring dail y living skills (what people actually do, or can 
do, without the assistance of others). It assesses adaptive behavior in 
individuals 5 -21 years of age.  
 
 Body Satisfaction Scales – The body satisfaction scales measure the level 
of satisfaction with body siz e, shape and weight.  
 
 HFI – The Home Food Inventory  is a valid assessment of the home food 
environment. Families will be mailed the HFI prior to the study 
appointment and will be asked to bring the completed survey to the study 
appointment.  
 
 Physical activ ity/armband diary – Participants will be asked to keep a 
record of the times that they did not wear the physical activity armband 
and of their activities on the days that they wore the armband. The diary 
packet will be sent home with each participant, alon g with a postage -paid 
envelope to return the diary.  
 
 Sense Wear® Armbands (Body Media, Inc): Participants will pi[INVESTIGATOR_676206]. The subject will be asked to wear the armband 
accelerometer for [ADDRESS_914210] is bathing/showering or if participating in water 
activities, such as swimming. Information collected will include the amount and 
intensity of physical/sedentary activities and sleep.  
 
 3 day die tary recalls: After the study visit, a nutritionist will contact [CONTACT_676230] 24 hours. This will be done three times (2 weekdays and 1 weekday).  
5.1.1 Labor atory Evaluations  
A fasting blood sample  will be performed for the laboratory evaluations described in section 
[IP_ADDRESS].  
 
[IP_ADDRESS]  Table: Clinical Laboratory Tests  
Tests   
Lipid panel (TG, TC, 
HDL -C, LDL -C) 
 Measured at CHOP Clinical Lab  
Non-HDL cholesterol  Calculated as Total cholesterol – HDL -C from the lipid 
  Protocol No. XXXXX  
   
   15 
panel  
Lipoprotein subclass 
analysis  By [CONTACT_676231], Inc. (Raleigh, NC) using NMR 
spectroscopy  
Blood glucose  Measured in duplicate at study site  on NOVA Biomedical 
STAT strip meter  
Plasma immunoreactive 
insulin  Measured in duplicate by [CONTACT_676232] -Insulin Resistance Index (HOMA -IR): 
[fasting insulin (ulU/mL) x fast ing BG(mmol/L)]/22.5  
Thyroglobulin antibody  
Thyroid peroxidase 
antibody  Measured at CHOP Clinical Lab  
Measured at CHOP Cl inical Lab  
High sensitivity C -reactive 
protein (hs -CRP)  Measured in the Penn CTRC TCL  
Interleukin 6 (IL -6)  Measured at CHOP CTRC Biochemistry Core Lab using  
R&D kits  
PAI 1  Measured at CHOP CTRC Biochemistry Core Lab  using 
R&D kits  
HbA1c  Measured at CHOP Clinical Lab  
  
  
Adiponectin & Leptin  Both measured in duplicate at CHOP CTRC Biochemistry 
Core Lab using Alpco kits  
TSH & T4  Measured at CHOP Clinical Lab  
[IP_ADDRESS]  Pregnancy Testing  
A urine pregnancy test will be performed for female subj ects who are ≥ 11 years old or who 
are menarchal  during the following visits: screening/baseline, 6 month, 12 month, and 18 
month.  A positive pregnancy result will be disclosed to the participant only. Pregnancy 
results will be disclosed to the parent/guardian if the subject gives the investigators 
perm ission. Subjects found to be pregnant during the visit will not be able to enroll in this 
study. The investigators will counsel the subject and guide them to seek the appropriate care.  
5.[ADDRESS_914211] m ixed effects pi[INVESTIGATOR_676198](2), 
implemented in the Sta ta v 12 program “xtmixed”, to estimate in a single model both 
longitudinal (within subject) and cross -sectional (across subject) effects of the intervention. 
Cross -sectional comparisons will be possible for the second [ADDRESS_914212] -specific baselin e z-score, and 
random slopes (for inter -subject variation in trajectories over time), will model and compare 
outcomes over time. Inclusion of quadratic terms for time, and implementation of splines, 
will avoid unrealistic assumptions of linear changes in o utcomes(25, 26). Baseline covariates 
and auxilia ry variables that predict dropout will be included to adjust for any residual 
imbalance and to meet the model assumption of dropout at random. Multiple imputations  
will be used for any missing covariates(27).  
 
Primary comparisons will assume complete treatment adherence. Using the methods of 
Nagelkerke(28) and Small(29), we will estimate the effect of the intervention among those 
subjects who adhered to treatment. Robust  confirmatory analysis will use generalized 
estimating equations weighted to adjust for dropout(30).  
 
Key contrasts will compare the level of each endpoint before and after treatment by 
[CONTACT_676233] -based expected values at the end of treatment and expected 
values at baseline; expected values arise from implementation of mixed effects models. This 
approach permits adjustment for relevant changes in patient characteristics over time (e.g. 
changes in growth and pubertal stat us) and for any baseline factors predicting dropout. 
Alternative contrasts will compare slopes of endpoints over time prior to the intervention 
against the slopes after treatment initiation. Pre -intervention measures will improve 
statistical power.  
 
Sensi tivity analyses will examine the potential impact of informative dropout(31), although 
this source of bias will be minimized through subject retention and follow -up after 
dropout(32). Supplementing models will be complete descriptive reports, including graphical 
displays of cholesterol and BMI -Z trajectories for each subject.  
 
Potential Problems/Feasibility: Dosing of levothyroxine treatment tends to be weight -
based and is not an exact science. The starting daily dose of 0.5 -1 mcg/kg/day is less than 
  Protocol No. XXXXX  
   
   17 
full replacement doses since TSH will be in the 5 -10 mUI/mL range and we wish to avoid 
“over-supplementing ” and suppressing TSH. TSH will be rechecked [ADDRESS_914213] “optimal” TSH levels and dose adjustments will be required. We expect that 
by [ADDRESS_914214] of intervention to be realized; in fact, 
the immediate treatment group will be followed for 12 months , over which time effects upon 
body composition and CMR factors should be apparent.  This s tudy might find that the 
relationship between subclinical hypothyroidism and CMR factors is pure association, an 
important finding as the medical community looks for evidence upon which to base 
management of “mild” TSH elevations in DS. In fact, this findi ng could avert unnecessary 
treatment of subclinical hypothyroidism in adolescents with DS.  
 
6.1.[ADDRESS_914215] for any relevant changes in patient characteristics over 
time (such as changes in growth and pubertal s tatus) as well as for any baseline factors that 
predict dropout. Alternative contrasts will compare the trajectories (slopes) of endpoints 
over time prior to the intervention against the slopes after the start of treatment.    
6.1.3 Safety Analysis  
To monitor fo r safety, data will be made available  to investigators every 3 months . Since the 
PI [INVESTIGATOR_676207], TSH data will 
be available to the PI [INVESTIGATOR_676208].  
6.2 Sample Size and Power  
Target sam ple size is 20, but 29 subjects will be enrolled to allow for dropout. Assuming 
that the dependent variables are continuous, the power calculations  using nonparametric 
tests that would be suitable for both continuous and ordered data  are listed below:  
Correlation over 
time Effect size of 
interaction (SD)  Power  
0.5 0.7 0.84 
0.6 0.6 0.71 
0.8 0.4 0.82 
  
6.3 Interim Analysis  
Interim efficacy or safety analyses will be done to monitor TSH levels in all subjects. 
Subjects with persistently elevated TSH (5 -10 mlU /mL) will be randomized for the 
  Protocol No. XXXXX  
   
   18 
treatment phase. If TSH is >10, a repeat test will be done within 1 -2 week s. If TSH remains 
>10, the subject will not be randomized.  Subjects that have TSH <[ADDRESS_914216] within 1 -2 weeks; this will be at the discretion of the study investigator. If TSH or repeat 
TSH (if applicable) is <5, the subject will be considered to have normal levels of TSH and 
will not qualify to continue the study.  
 
 
  Protocol No. XXXXX  
   
   19 
7 STUDY MEDICATION (IN TERVENTION)  
7.1 Description  
Levothyroxine sodium tablets, USP contain synthetic crystalline L -3,3',5,5' -
tetraiodothyronine sodium salt [levothyroxine (T 4) sodium]. Synthetic T 4 is identical to that 
produced in the human thyroid gland .   50 mcg levothyroxine tablets will be prescribed for 
anticipated doses ranging from 25 – 100 mcg/day  (0.5-1 mcg/kg/day) .  
The placebo  is generic lactase manufactured by [CONTACT_676234]. Each caplet  
contains 3,000 FCC units of lactase enzyme (active in gredient). Inactive ingredients are: 
crospovidone, dicalcium phosphate, magnesium stearate, mannitol, microcrystalline 
cellulose, polyalditol, silicon dioxide, sodium citrate.  
7.1.1 Packaging  
A 3 month supply of tablets will be packaged in a child safe prescript ion container.  
7.1.2 Labeling  
Both levothyroxine and the generic lactase tablets are available commercially and will be 
labeled appropriately by [CONTACT_3455]. The investigational pharmacy will transfer a 3 -
month supply of tablets into a child -resistant vial and label with a patient -specific label that 
complies with all the federal, state and CFR requirements.  
7.1.3 Dosing  
Levot hyroxine daily dose of 0.5 – 1 mcg/kg/day by [CONTACT_345920].  
7.1.[ADDRESS_914217] be  returned to the Study Coordinator . 
  Protocol No. XXXXX  
   
   20 
8 SAFETY MANAGEMENT  
 
8.1 Clinical A dverse Events  
Clinical adverse events (AEs) will be monitored throughout the study. Following 
randomization, adverse events will be monitored using: (a) Home diary of adverse events 
(AE), rated by [CONTACT_2236] (mild, moderate, severe). (b) Interview at each s tudy visit to 
document intensity and frequency of AE.  
8.[ADDRESS_914218] who has received an 
intervention (drug, biologic, or other intervention).  The occurrence does not necessarily 
have to have a causal relationship with the treatment.  An AE can therefore be any 
unfavorable or unintended sign (includ ing an abnormal laboratory finding, for example), 
symptom, or disease temporally associated with the use of a medicinal product, whether or 
not considered related to the medicinal product.  
All AEs (including serious AEs) will be noted in the study records and on the case report 
form with a full description including the nature, date and time of onset, determination of 
non-serious versus serious, intensity (mild, moderate, severe), duration, causality, and 
outcome of the event.  
8.4 Definition of a Serious Advers e Event (SAE)  
An SAE is any adverse drug experience occurring at any dose that results in any of the 
following outcomes:  
 death,  
 a life -threatening event (at risk of death at the time of the event),  
 requires inpatient hospi[INVESTIGATOR_27588],  
 a persistent or significant disability/incapacity, or  
 a congenital anomaly/birth defect in the offspring of a subject.   
Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_128151] c onsidered a serious adverse drug event when, based upon 
appropriate medical judgment, they may jeopardize the subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this definition.  
  Protocol No. XXXXX  
   
   [ADDRESS_914219] udy intervention should be characterized using one of 
the following terms in accordance with CHOP IRB Guidelines: definitely, probably, 
possibly, unlikely or unrelated.  
8.5 IRB/IEC Notification of SAEs  and Other Unanticipated Problems  
The Investigator will pr omptly notify the IRB of all on -site unanticipated, serious Adverse 
Events that are related to the research activity. Other unanticipated problems related to the 
research involving risk to subjects or others will also be reported promptly. Written reports 
will be filed using the eIRB system and in accordance with the timeline below. External 
SAEs that are both unexpected and related to the study intervention will be reported 
promptly after the investigator receives the report.  
Type of Unanticipated 
Problem  Initial Notification  
(Phone, Email, Fax)  Written Report  
Internal (on -site) SAEs       
Death or Life Threatening  24 hours  Within 2 calendar days  
Internal (on -site) SAEs  
All other SAEs  7 days  Within 7 business days  
Unanticipated Problems 
Related to Research  7 days  Within 7 business days  
All other AEs  N/A Brief Summary of important 
AEs may be reported at time 
of continuing review  
8.5.1 Follow -up report  
If an SAE has not resolved at the time of the initial report and new information arises that 
changes th e investigator’s assessment of the event, a follow -up report including all relevant 
new or reassessed information (e.g., concomitant medication, medical history) should be 
submitted to the IRB. The investigator is responsible for ensuring that all SAE are followed 
until either resolved or stable.  
8.[ADDRESS_914220] be consistent with regulatory, sponsor or GCRC requirements (if applicable)  
  Protocol No. XXXXX  
   
   22 
8.7 Medical Emergencies   
Medical emergencies that might develop during the course of the study would be referred to 
the patient’s local emergency room.  
9 STUDY ADMINISTRATION  
9.1 Treatment Assignment Methods  
9.1.1 Randomization  
Only subjects with persistently elevated TSH (>5mlU/mL) at 6 months will be recruited for 
the randomization phase. After 6 months of observation, subjects will be randomized to one 
of two treatment arms . 
1) 6 months of placebo followed by 6 months of levothyroxine  
2) 12 months of   levothyroxine   
9.1.2 Blinding  
Subjects/families will be blinded to treatment arm . Investigators will not be blinded  to 
permit titration of levothyroxine dose.   
9.1.3 Unblinding  
At the conclusion of the study, subjects/families will be notified o f the treatment arm they 
received.   
9.2 Data Collection and Management  
The CHOP CTRC Informatics Cor e will create case report forms (CRF) and a REDCap 
database for data capture. REDCap is an NIH-supported web -based data management 
software designed by [CONTACT_300914]. Using REDCap checking tools, 
the BDMC  will confirm completeness and  valid values and will inform the investigative 
team of any errors or omissions for prompt resolution. Data entered in REDCap will be 
exported for use with Stata and SAS statistical packages as needed for immediate access to 
the research team.    
The PIs are responsible for the accuracy and completeness of data collection and 
management. The PIs may designate qualified individual(s) to collect data and manage data. 
Only investigators and research staff that have completed appropriate IRB training and 
appro val and are listed on the IRB approved protocol are eligible to collect and work on 
information from the study. Future studies that may use patients or data collected from this 
study must have separate approved IRB protocols and consent forms, if applicabl e. 
Recruitment data will be recorded onto the screening questionnaire  after the verbal consent 
is recorded.  Original data will be recorded directly onto CRFs by [CONTACT_236332] a 
study investigator. Copi[INVESTIGATOR_201705], physical exam, anthropomet ric, DXA, PWV, and 
PWA results will be received through inter -office mailing, pi[INVESTIGATOR_300874], and 
sometimes through email. This information also will be recorded onto CRFs while the 
originals may be kept at the testing site (CHOP Outpatient CTRC)  or wi th the study 
investigative staff . CRFs will be kept in a locked filing cabinet in a locked room at all times. 
  Protocol No. XXXXX  
   
   [ADDRESS_914221] 
access to view/edit data of all subjects. Note that only limited PHI (date of visit, date of 
birth) is included in the REDcap database. CHOP will have read -write access for data 
collected at both sites. CHOP will require acc ess to edit records for both sites because 
several evaluations will be analyzed at CHOP, and reports including data from both CHOP 
and CNMC sites will be forwarded to the CHOP team, who will then import or enter the 
data into REDCap. Written informed conse nt granting permission for other site(s) to access 
PHI will be obtained from all subjects. The CRF and  REDcap database  will be designed by 
[CONTACT_300917].  
All data and records generated during this study will be kept confidential in accordan ce with 
institutional policies and on HIPPA subject privacy. The investigators/study team 
members/site personnel will not use such data and records for any purpose other than for 
conducting the study.  
As a way to minimize the chance of PHI (protected healt h information) from being 
disclosed, a unique identification code will be used for each participant. The key to this code 
will be kept in a locked file in the PI/Study Coordinator’s office.  
If any publications result from this research, the participant wi ll not be identified by 
[CONTACT_2300]/PHI.  
The information collected as part of this study will be kept for 6 years or until the 
completion of the study (whichever is longer). At that time, the information collected will be 
destroyed or all identifiable information  will be removed. All keys will be destroyed at this 
time, as well.  
 
9.[ADDRESS_914222] obtaining IRB approval. The 
investigator will obtain a data use agreement between the provider (the PI) of the data and 
any recipi[INVESTIGATOR_66945] a limited dataset ( PHI limited to dates and zip 
codes).  
  Protocol No. XXXXX  
   
   24 
9.4 Regulatory and Ethical Considerations  
9.4.1 Data and Safety Monitoring Plan  
Study progress and safety will be reviewed quarterly (and more frequently if needed) by [CONTACT_1600]. Review of the rate of subject accrual, adherence to inclusion/exclusion criteria will occur 
quarterly to assure that participants meet the eligibility criteria. There will be ongoing 
collection of data on adverse events and compliance to the treatment pro tocol throughout the 
study by [CONTACT_3647], which will be reviewed monthly by [CONTACT_300918]. If there is 
an incidental finding deemed by [CONTACT_978]  [INVESTIGATOR_300875], the primary care provider 
will be notified. The parent/guardian will be not ified and asked to follow up with the 
subject’s primary care provider if during the visit a subject is noted to have blood pressure 
that is ≥ the 95th percentile for age, gender, and height. We will notify the 
parent/guardian/primary care provider with cli nically relevant abnormal labs. Specifically,  
these include:  lipid levels/insulin levels/blood glucose levels  /TSH and T4.  Note that some 
labs, such as lipi[INVESTIGATOR_300876], are run in batches and reporting of results may be delayed.  
Data Monitoring Board ( DSMB)  -- Interim monitoring and analysis  
A data safety monitoring board (DSMB) will be established: (1) to protect study patients, (2) 
to safeguard their interests, (3) to monitor the overall conduct of the trial, (4) to help to 
protect the integrity of t he trial, and (5) to supervise the conduct of any interim analyses.   
Specific rules and protocols for all reviews will be established in a formal protocol, and 
approved by [CONTACT_4318], prior to the first DSMB meeting.  The DSMB will work jointly 
with the tri al statisticians and clinical investigators to establish specific criteria to 
accomplish its tasks. The DSMB will consist of at least four members including a 
biostatistician, a developmental pediatrician from outside Children’s Hospi[INVESTIGATOR_133445], a  pediatric endocrinologist, and a senior faculty member with experience in 
clinical research and in care of children and adolescents with complex chronic illness. The 
DSMB will choose its chair.   
The Project PI  [INVESTIGATOR_676209], documenting them  
on an Adverse Experience Report (AER) form, and then reporting them regularly to the  
DSMB (33) . 
The DSMB will meet annually to review efficacy issues and adverse events, and will have 
additional conference calls as needed.  Annual reports will be prepared for them by [CONTACT_676235]. The DSMB will independently evaluate whether ad verse 
events constitute grounds to discontinue the study.  
The DSMB will report to the trial principal investigators within one month of the start of the 
DSMB meeting, or earlier if patient safety becomes an issue.   Early stoppi[INVESTIGATOR_676210]; owin g to the small sample 
size, there will be no formal early stoppi[INVESTIGATOR_676211].    
 
DSMB reporting; Independence of DSMB and study trial leadership  
All data and the interim analyses will be conducted by [CONTACT_676236], independently from the trial leadership and staff.    The DSMB report will 
consist of the following elements:  
 
  Protocol No. XXXXX  
   
   [ADDRESS_914223] are as follows:  
 Blood draw may result in temporary discomfort from the needle stick, bruising, 
fainting, weakness, and rarely an infection at  the site  
 Anthropometric measurements and pubertal status exam pose minimal risks  
 Exposure to radiation during DXA scan  
 Sharing of private health information (PHI) including dietary intake, demographic 
information, health history and medical information  
 Pulse wave velocity and pulse wave analysis pose minimal risks  
 12 hour overnight fasting may cause hunger pangs, upset stomach, headache, or 
light-headedness  
 Blood pressure measurement by [CONTACT_676237]/tingling in the arm  
 SenseWea r® Armbands  worn for 7 consecutive days may cause skin irritability  
 Sensitive psychosocial issues may arise during questionnaire assessment  
A small amount of blood (about 3 teaspoons) will be drawn at major assessment points. 
Adolescents may experience some degree of discomfort, bruising, or lightheadedness 
with fasting blood draws. There is also a risk of infection when blood is drawn. These 
occurrences are rare, generally mild, and respond to conservative treatment.  
Participation in the study involves risks associated with the small amount of radiation 
exposure associated with the DXA whole body scan for body composition assessment; 
the total radiation EDE from DXA scans is less than 3 μSv (or 1 mrem). This total 
amount of radiation is less than the exp osure to daily background radiation at sea level 
(3,000 μSv per year) and is therefore considered minimal risk. Females of childbearing 
potential undergo a urine pregnancy test prior to the DXA scans. Pregnant females do 
not have DXA scans performed in ord er to protect the unborn fetus.  
  Protocol No. XXXXX  
   
   [ADDRESS_914224] in a private 
setting. The procedure will be explained to the child in advance, and the parent is 
permitted to be present if preferred by [CONTACT_2252]. The exam is performed by [CONTACT_676238].  
SenseWear® Armbands (Body  Media, Inc.).  There is little to no risk associated with 
measuring physical activity, sedentary behavior, and sleep with armband accelerometers.  
These accelerometers fit comfortably on the participant’s arm and can easily be removed 
should he/she become uncomfortable. Some patients may experience skin irritation, 
particularly when sweating, with the devices in which case they can adjust them or in  
rare instances, remove them if necessary. To prevent irritation, parents will be instructed 
to clean the armband with mild soap and water when the child removes it to bath e or 
shower. If irritation does occur, parents will be instructed to use Aquaphor or  Vaseline 
where the fabric of the band is to treat and prevent further irritation. If a child is allergic 
to metal they will not be required to complete this assessment.  
A licensed clinical psychologist with expertise in working with children and 
adolescen ts, will meet with families concerning sensitive psychosocial issues that may 
arise during assessments or intervention. Any emotional upset will be handled with 
appropriate support to the participants and their caregivers. Further, if a behavioral 
health c oncern arises during the study needing further evaluation and treatment, the 
clinical psychologist  will assist with a referral . 
If a subject shows any signs of clinical instability or definitively decides to discontinue 
participation, the study visit will end. 
Protection against risks associated with thyroid hormone treatment  
 
Children and adolescents with subclinical hypothyroidism are commonly treated with 
thyroid hormone replacement, even in the absence of data supporting treatment.  
Similarly, subclinical hypothyroidism is frequently treated in the setting of DS 
despi[INVESTIGATOR_040] a dearth of evidence to support or negate intervention.  The primary risk of 
thyroid hormone treatment in this 6 month observation followed by 6 -12 month 
intervention study is ex cessive replacement leading to relative hyperthyroidism with 
TSH suppression; short -term symptoms include restlessness, irritability, tachycardia, 
palpi[INVESTIGATOR_814], poor sleep, and weight loss. To minimize these risks:  
 
 The family will be instructed to observe  and report these symptoms/signs to the 
study team  
 TSH and T4 will be checked if signs/symptoms develop  
  Protocol No. XXXXX  
   
   27 
 TSH and T4 will be checked 6 weeks after levothyroxine initiation, the time 
required to reach steady state;  the dose will be titrated to maintain TSH i n the normal 
range  
 If the initial TSH is within range, TFTs will be checked in another 14 weeks, sooner 
if symptoms arise  
 If a TSH is elevated or suppressed, the dose will be adjusted and TFTs repeated in 6 
weeks to reassess thyroid status  
 
The dose of levothyroxine replacement (0.5 -1 mcg/kg/dy) is not expected to cause TSH 
suppression and symptoms of hyperthyroidism.  A dose of 1 mcg/kg/day is used in the 
treatment of subclinical hypothyroidism in adults and is much lower than typi[INVESTIGATOR_676212] d oses of 4 -5 mcg/kg/day for age 6 -12y; 2 -3 mcg/kg/day for age>12 y but 
growth and puberty incomplete; and 1.7 mcg/kg/day for children in whom growth and 
puberty are complete.  In fact, chronic suppressive doses of levothyroxine are routinely 
used following thyroidectomy and radioactive iodine ablation for thyroid cancer in adults 
and children.  For children, this treatment means TSH is maintained in the low range (TSH 
< 0.1 mIU/L). (34); the major concern is the impact of years of suppressive therapy upo n 
bone health. In this study, TSH will be measured and dose adjustments made for low TSH; 
thus, any subclinical hyperthyroidism induced by [CONTACT_676239].  
Morbidity from acute levothyroxine  intoxication requires massive doses of levot hyroxine  
(> 5-10 mg) and is not anticipated.  The study team will remind families that, as with all 
medications, administration should be supervised by a parent and medications maintained 
out of reach of children.  
The study team will review potential side effects and toxicities with subjects by [CONTACT_756] [ADDRESS_914225] who develops TSH>10 mIU/L during the 
course of the study will have a repeat TSH test done within 1 -2 week s. If the repeat TSH 
remains >10  mIU/mL , the subject will be withdrawn from the study  and r eferred to 
endocrinology for management of hypothyroidism.  If a suppressed TSH (TSH <0.1 
mIU/L) is identified in a child on placebo, the TSH will be repeated within [ADDRESS_914226] will be referred to endocrinology fo r management 
of possible hyperthyroidism.  If a suppressed TSH (TSH <0.1 mIU/L) is identified in a 
child on levothyroxine , the levothyroxine  dose will be decreased and the lab repeated 
within [ADDRESS_914227]  subclinical hypo thyroid disease (elevated TSH >5 -10 mlU/mL)  will be treated 
with levothyroxine . If a subject’s TSH is > 10 mlU/L during the observation period,  a repea t 
TSH test will be done within 1 -2 week s. If the repeat TSH is >10 mIU/mL,  the thyroid 
dysfunction will not be considered subclinical and the subject will be referred to an 
endocrinologist for definitive therapy.  Participants may indirectly benefit from 
identification of abnormalities such  as diabetes, dyslipi[INVESTIGATOR_035], and hypothyroidism from the 
fasting blood draw . If clinically relevant abnormalities are found, the family will be notified. 
With the consent from the family, clinically relevant tests results will be shared with the 
subject’s p rimary care physician.  Only studies performed by [CONTACT_676240]. Participants found to have an impaired fasting glucose will be referred 
appropriately  for further management and treatment.  
9.4.4 Risk -Benefit Assessment  
The benefits to part icipation in this trial outweigh the potential risks.  Levothyroxine  is used 
in treating subclinical hypothyroidism with few side effects.  
9.5 Recruitment Strategy  
Subjects from the corresponding study, IRB #9233  who consent to screened for this study 
(IRB #95 78) may be recruited if they meet eligibility criteria based on the information 
collected at the #9233 study visit.  Subjects may also be  recruited from CHOP’s Pediatric 
Research Consortium (PeRC)  and Recruitment Enhancement Core , the CHOP Clinical 
Research  Finder,  CNMC Primary Care sites, Endocrinology and Trisomy [ADDRESS_914228] recruitment will e -mail registry participants the IRB -approved 
recruitment flyer.  
9.6 Informed Consent/Assent  and HIPAA Authorization  
For subjects recruited from IRB #9233:  
The first #9578 visit for these subjects  recruited from IRB #9233  will be Blood Draw Visit 
A. Prior to Blood Draw Visit A, verbal consent from the parent/guardian/legal authorized 
representative will be obtained and documented by [CONTACT_9137]/study investigator.  
A description of the procedures involved in Bloo d Draw Visit A, as well as the 
risks/benefits , will be provided verbally as part of this process. Additionally, it will be 
stressed that any questions are appropriate and that all aspects of the study are voluntary. 
Assent may not be obtained for screening  purposes if the child subject is not available at the 
time of the phone call or is not cognitively able.  
If the subject is eligible to continue to Study Visit #2, written informed consent for the entire 
study will be obtained prior to conducting Study Vis it #2 procedures. The written informed 
consent process will be the same as described below for subjects who are not recruited from 
IRB #9233.  
  Protocol No. XXXXX  
   
   29 
For subjects not recruited from IRB #9233:  
Subjects not recruited from IRB #[ADDRESS_914229] an initial telephone s creening interview; 
those who are eligible based on the study inclusion/exclusion criteria will be invited to 
participate . 
Prior to conducting the screening interview, verbal consent from the parent/guardian/legal 
authorized representative will be obtained  and documented by [CONTACT_9137]/study 
investigator. A description of the procedures involved in the study, as well as the 
risks/benefits will be provided verbally as part of this process. Additionally, it will be 
stressed that any questions are ap propriate and that all aspects of the study are voluntary.  
Assent may not be obtained for screening purposes if the child subject is not available at the 
time of the phone call or is not cognitively able.  
Prior to conducting the study visit procedures, written informed consent will be obtained 
from the parents/guardians of children and adolescents with DS. Assent will be obtained 
from children who, by [CONTACT_11486], are at a first grade or [ADDRESS_914230] sufficient capacity.   
The consent/assent process will take place in a private consent room. It will be stressed 
again that participation in the study is v oluntary and that any questions can and should be 
raised. Consent and assent will be documented by [CONTACT_7071]/guardian/participant’s 
signatures on the approved consent documents. A description of the procedures involved in 
the study, as well as the risks a nd benefits, will be provided verbally as part of the consent 
process.  
Consent/assent documents will be maintained in the participant’s study file and documented. 
The parent/guardian will receive a copy of the signed document(s).    
9.6.1 Consent for Down syndro me subjects 18 – 20 years of age  
For the screening and telephone verbal consent processes, consent will not be obtained for 
Down syndrome subjects 18 -20 years of age.  
Consent will be obtained  from Down syndrome subjects aged 18 -20, when possible, during 
the in -person written informed consent process that will  occur at either Study Visit #1 or Study 
Visit #2.  Ability to provide consent will be ascertained by [CONTACT_3476]. Initially, the team 
will assess the participants’ ability by [CONTACT_676241] a brief, general 
sense of their ability to comprehend and communicate. If ability to provide consent seems 
likely, the team will then explain the following to confirm that the study participant 
understands all of the essential element s of the consent form:  
a. The purpose of the research study. We will explain that the study is trying to 
understand if thyroid pi[INVESTIGATOR_676213]. XXXXX  
   
   [ADDRESS_914231]’s legally authorized representative/health care 
representative will provide the written informed consent on the subject’s behalf.  
Assent Procedures  
Assent will be obtained and documented on  the consent form for children capable of 
assenting.  DS subjects age [ADDRESS_914232] assent documented in the consent form.  If the capability of some of the 
participants is limited in comprehe nding the study and that they cannot reasonably be 
consulted, assent will not be obtained in these cases; the investigators will document it on 
the consent form. Investigators will obtain assent whenever possible.  
9.6.2 Waiver of Documentation of Consent  
Waiver of documentation of consent is being sought for screening procedures, as the 
parent/guardian/legal authorized representative may be contact[CONTACT_676242] 
a signature [CONTACT_300933]. As described in ( 9.6), verbal consent will be obtaine d and 
documented by [CONTACT_9137]/study investigator prior to conducting the screening 
interview.  
 
9.6.3 Waiver of Assent  
Waiver of assent is being sought for screening procedures, as subjects may not be present 
when parents/guardians/legally authorized  representatives are contact[CONTACT_676243]. XXXXX  
   
   31 
 
9.7 Payment to Subjects/Families  
All study procedures and expenses will not be billed to the participant. The total 
compensation can be up to $ 815 for the entire study.  
Study Visit #1 (0 month) : The total reimbursement for Study  Visit #1  is $150.  The  
parent/guardian will receive  a total of  $[ADDRESS_914233] to offset the burdens of 
transportation/parking/time off work/baby[CONTACT_300928]/meals. The bankcard will be loaded 
with $50 immediately after the study visit and with an additional $[ADDRESS_914234] -visit 
procedures are complete.  The participant will receive a $[ADDRESS_914235] 
the study.  
Blood Draw Visit A  (3 month) : For Blood Draw Visit A , the subject will receive $[ADDRESS_914236]  for their time and efforts.    
Study Visit #2 (6 month) : The total reimbursement for Study Visit #2  is $105. The 
parent/guardian will receive  a total of  $[ADDRESS_914237] to offset the burdens of 
transportation/parking/time off work/baby[CONTACT_300928]/meals.  The bankcard will be loaded 
with $50 immediately after the study visit and with an additional $[ADDRESS_914238] -visit 
procedures are complete.   The participant will receiv e a $ [ADDRESS_914239] plus a small gift worth 
$5.[ADDRESS_914240] the study.  
Blood Draw Visit B  (7.5 month) : For Blood Draw Visit B , the subject will  receive $[ADDRESS_914241]  for their time and efforts.   
Study Visit #3 (12 month) : The tot al reimbursement for Study Visit #3 is $105. The 
parent/guardian will receive a total of $[ADDRESS_914242] to offset the burdens of 
transportation/parking/time off work/baby[CONTACT_300928]/meals.  The bankcard will be loaded 
with $50 immediately after  the study visit and with an additional $ [ADDRESS_914243] -visit 
procedures are complete.  The participant will receive a $ [ADDRESS_914244] plus a small gift worth 
$5.[ADDRESS_914245] the study.  
Blood Draw Visit  C (13.5 month) : For Blood Draw Visit C, the subject will receive $[ADDRESS_914246] for their time and efforts.   
Study Visit #4 (18 month) : The total reimbursement for Study Visit #4  is $105. The 
parent/guardian will receive a total of $[ADDRESS_914247] to offset the burdens  of 
transportation/parking/time off work/baby[CONTACT_300928]/meals.  The bankcard will be loaded 
with $50 immediately after the study visit and with an additional $ [ADDRESS_914248] -visit 
procedures are complete.  The participant will receive a $ [ADDRESS_914249] us a small gift worth 
$5.[ADDRESS_914250] the study.  
Additional  TSH & T4 Checks:  In the case of dose adjustments  or TSH >10 , subjects will  
receive $[ADDRESS_914251] their blood draw n to check TSH 
and/or T4 level s. Up to 3 TSH and T4 checks may be necessary  in the event of dose 
adjustment(s)  or TSH > 10. Subjects will receive up to $75.00 for the se TSH & T4 checks.  
  Protocol No. XXXXX  
   
   32 
In rare circumstances, participants may not be able to complete all study procedures on the 
date of their study visit (for example, if a machine is broken). If this occurs, we would like 
to compensate the parent/guardian with an additional $[ADDRESS_914252]. This additional 
compensation will be an option for the 4 study visits.  
 
10 PUBLICATION  
The results of this study may be submitted for consideration for presentations at national 
meetings and/or publication in academic journals. At no time will any PHI from this study 
be disclosed for any presentation(s) or journal article(s).  
 
11 REFERENCES  
 
1. American Academy of Pediatrics: Health supervision for children with Down 
syndrome. Pediatrics. 2001;107(2):[ADDRESS_914253] N, Ware J. Applied Longitudinal Analysis. [LOCATION_001]: John 
Wiley & Sons; 2003.  
3. Razvi S, Wea ver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart 
disease and mortality in people with subclinical hypothyroidism: reanalysis of the 
Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95(4):1734 -40. 
4. Biondi B, Cooper DS. The clinical s ignificance of subclinical thyroid dysfunction. 
Endocr Rev. 2008;29(1):[ADDRESS_914254] velocity in subclinical hypothyroidism. J Clin Endocrinol Metab. 
2006;91(1):154 -8. 
6. Lekakis J, Papamichael C, Alevizaki M, Pi[INVESTIGATOR_300881] G, Marafelia P, Mantzos J, et al. 
Flow -mediated, endothelium -dependent vasodilation is impaired in subjects with 
hypothyroidism, borderline hypothyroidism, and high -normal serum thyrotropin (TSH) 
values.  Thyroid. 1997;7(3):411 -4. 
7. Taddei S, Caraccio N, Virdis A, Dardano A, Versari D, Ghiadoni L, et al. Impaired 
endothelium -dependent vasodilatation in subclinical hypothyroidism: beneficial effect of 
levothyroxine therapy. J Clin Endocrinol Metab. 2003;88 (8):[ADDRESS_914255] 
of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in 
subclinical hypothyroidism: randomized, crossover trial. J Clin Endo crinol Metab. 
2007;92(5):[ADDRESS_914256] PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is 
associated with a low -grade inflammation, increased triglyceride levels and predicts 
cardiovascular disease in males below 50 years. Clin Endoc rinol (Oxf). 2004;61(2):232 -8. 
10. Ozcan O, Cakir E, Yaman H, Akgul EO, Erturk K, Beyhan Z, et al. The effects of 
thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and 
  Protocol No. XXXXX  
   
   33 
other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. 
Clin Endocrinol (Oxf). 2005;63(2):203 -6. 
11. Tuzcu A, Bahceci M, Gokalp D, Tuzun Y, Gunes K. Subclinical hypothyroidism 
may be associated with elevated high -sensitive c -reactive protein (low grade inflammation) 
and fasting hyperinsulinemia. Endocr J. 2005;52(1):89 -94. 
12. Hueston WJ, Pearson WS. Subclinical hypothyroidism and the risk of 
hypercholesterolemia. Ann Fam Med. 2004;2(4):351 -5. PMCID: 1466694.  
13. Bauer DC, Ettinger B, Browner WS. Thyroid functions and serum lipid s in older 
women: a population -based study. Am J Med. 1998;104(6):546 -51. 
14. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. Lipid 
profiles and cardiovascular disease in the Whickham area with particular reference to 
thyroid failure . Clin Endocrinol (Oxf). 1977;7(6):495 -508. 
15. Bakker SJ, ter Maaten JC, Popp -Snijders C, Slaets JP, Heine RJ, Gans RO. The 
relationship between thyrotropin and low density lipoprotein cholesterol is modified by 
[CONTACT_676244]. J Clin Endocrinol Metab. 2001;86(3):1206 -
11. 
16. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, et al. TSH -
controlled L -thyroxine therapy reduces cholesterol levels and clinical symptoms in 
subclinical hypothyroidism: a double blin d, placebo -controlled trial (Basel Thyroid Study). J 
Clin Endocrinol Metab. 2001;86(10):[ADDRESS_914257]? 
Eur J Endocrinol. 2008;159(3):343 -5. 
18. Paoli -Valeri M, Guzman M, Jim enez-Lopez V, Arias -Ferreira A, Briceno -Fernandez 
M, Arata -Bellabarba G. [Atherogenic lipid profile in children with subclinical 
hypothyroidism]. An Pediatr (Barc). 2005;62(2):128 -34. 
19. Cetinkaya E, Aslan A, Vidinlisan S, Ocal G. Height improvement by L -thyroxine 
treatment in subclinical hypothyroidism. Pediatr Int. 2003;45(5):[ADDRESS_914258]. 1989;93(6):652 -6. 
21. van Trotsenburg AS, Vulsma T, van Santen HM, Cheung W, de Vijlder JJ. Lower 
neonatal screening thyroxine concentrations in down syndrome newborns. J Clin Endocrinol 
Metab. 2003;88(4):[ADDRESS_914259] of thyroxine treatment started in the neonatal period on 
development and growth of two -year-old Down syndrome children: a randomized clinical 
trial. J Clin Endocrinol  Metab. 2005;90(6):3304 -11. 
23. Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Anneren G. Thyroid dysfunction 
in Down's syndrome: relation to age and thyroid autoimmunity. Arch Dis Child. 
1998;79(3):242 -5. PMCID: 1717691.  
24. Carroll KN, Arbogast PG, Dudl ey JA, Cooper WO. Increase in incidence of 
medically treated thyroid disease in children with Down Syndrome after rerelease of 
American Academy of Pediatrics Health Supervision guidelines. Pediatrics. 
2008;122(2):e493 -8. PMCID: 2666985.  
  Protocol No. XXXXX  
   
   [ADDRESS_914260] NM, Ware JH. Applied longitudinal analysis. Hoboken, N.J.: 
Wiley -Interscience; 2004.  
26. Gurrin LC, Scurrah KJ, Hazelton ML. Tutorial in biostatistics: spline smoothing with 
linear mixed models. Stat Med. 2005;24(21):3361 -81. 
27. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol 
Methods. 2002;7(2):147 -77. 
28. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in 
randomized clinical trials in the presence of non -compliance. Stat Med. 2000;19(14):[ADDRESS_914261] TR, Joffe MM, Cheng J. Random effects logistic models for 
analysing efficacy of a longitudinal randomized treatment with non -adherence. Stat Med. 
2006;25(12):[ADDRESS_914262] ; [LOCATION_001]: Oxford 
University Press; 2002.  
31. Daniels MJ, Hogan JW. Missing data in longitudinal studies : strategies for Bayesian 
modeling and sensitivity analysis. Boca Raton: Chapman & Hall/CRC; 2008.  
32. National Research Council (U.S.). Panel on Handling Missing Data in Clinical 
Trials., National Research Council (U.S.). Committee on National Statistics., National 
Academies Press (U.S.). The prevention and treatment of missing data in clinical trials. 
Washington, D.C.: National Academies Press; 20 10. 
33. Group DS. A proposed charter for clinical trial data monitoring committees: helpi[INVESTIGATOR_676214]. Lancet. 2005;365(9460):711 -22. 
34. Dinauer CA, Breuer C, Rivkees SA. Differentiated thyroid cancer in children: 
diagnosis and management.  Curr Opin Oncol. 2008;20(1):59 -65. 
 
 
 
 